Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mettler-Toledo Introduces New Webinar

Published: Friday, October 26, 2012
Last Updated: Friday, October 26, 2012
Bookmark and Share
Webinar explains how pharma manufacturers can optimize fermentation process.

Mettler-Toledo Process Analytics has released a new webinar intended for pharmaceutical producers involved in biofermentation.

The webinar explains how optimal microorganism growth conditions and consequently higher process yield can be achieved through a program of dissolved carbon dioxide measurement and control.

In biopharmaceutical operations, it is important that process reliability is high at all times. Central to this aim is timely measurement of analytical parameters.

Well known key process parameters include pH, dissolved oxygen, and turbidity. Less recognized but of significant importance in fermentation reactors is carbon dioxide.

Dissolved carbon dioxide levels can be indicative of the quality of cellular metabolism.

High levels of CO2 generally equate to high cellular growth; however, if CO2 levels are excessive, they can reach a concentration that is toxic to the microorganisms.

Low CO2 levels lead to a slow growth rate and extended process duration. In-line CO2 measurement systems provide continuous, real-time data on CO2 concentration levels, allowing rapid corrective action when required.

Mettler-Toledo’s on-demand webinar illustrates how dissolved CO2 measurement and control can keep fermentation cultures in their optimal growth range.

This consequently increases process yield and efficiency of the fermentation process.

The webinar also introduces Mettler-Toledo's InPro 5000i dissolved CO2 sensor, which has been designed specifically for the requirements of the pharmaceutical industry. The webinar is available at www.mt.com.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
DNA-Based Zika Vaccine Showed Protection From Infection, Brain Damage and Death
The study is the first of its kind to analyze a vaccine in an animal model that is susceptible to the disease, providing information regarding the protective impact of the immune response in susceptible individuals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!